Developing The Next Generation Of Pain Management & Mental Health Therapies
Three Drug Candidates
Three Fully Funded Clinical Development Programs
About Nexalis Therapeutics
Nexalis Therapeutics is a clinical-stage biopharmaceutical company advancing next-generation therapies for pain and mental health, targeting large, underserved markets with significant unmet need.
Learn MoreThree differentiated clinical drug candidates advancing through development
Focused on two high-value therapeutic areas with strong commercial demand
Proprietary oral and inhaled delivery platforms designed to improve efficacy and patient outcomes
Total funding facility of $52.3M, providing runway to key clinical milestones
Active clinical programs progressing toward value-inflection points
Seasoned leadership team with a track record of execution in drug development
Therapeutic Areas
We are developing innovative therapies across two critical therapeutic areas - pain management and mental health - using both oral and inhaled drug delivery modalities.
Our pipeline targets conditions with significant unmet medical needs, including treatment-resistant depression, breakthrough cancer pain, and panic disorder.
By leveraging the FDA 505(b)(2) regulatory pathway, we can accelerate development timelines while building on established safety profiles.